Health Care Down on FDA Concerns -- Health Care Roundup

Health-care companies slipped amid concerns about upheaval at the U.S. drug regulatory agency.

The departure of Food and Drug Administration official Dr. Nicole Verdun, who was in charge of regulating gene therapies and cell therapies, is setting off a new round of worries for biotech investors, two months after the fiery resignation of another senior FDA regulator, Dr. Peter Marks.

Write to Rob Curran at [e-mail]

(END) Dow Jones Newswires

06-20-25 1740ET